TG Therapeutics, Inc. Stock News

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year.

None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but generally in line with management expectations of a softer Q3. Now we wait for the important updates in early 2025 — preliminary Q4 net sales of Briumvi, the guidance for 2025, and the preliminary results from...

TG Therapeutics' Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and increased R&D investments, despite Briumvi's revenue growth. Briumvi, a CD20-directed monoclonal antibody for multiple sclerosis, generated $83.3 million in Q3, showing a 15% QoQ growth but a deceleration in revenue growth. The Company raised its full-year revenue guidance to $300-305 million...

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Ed White - H.C. Wainwright Michael DiFiore - Everco...

TG Therapeutics stock crashed Monday after missing profit expectations, though sales of its multiple sclerosis treatment beat forecasts. The post TG Therapeutics Crashes — Reversing A Breakout — On Its Mixed Third-Quarter Results appeared first on Investor's Business Daily.

Holly Springs, North Carolina site to provide security of supply for B-cell therapy for relapsing multiple sclerosis Holly Springs, North Carolina site to provide security of supply for B-cell therapy for relapsing multiple sclerosis

Two of the five top stocks to watch this week target the artificial intelligence market. The post AI Stocks Meta, Oracle Lead Five Names Near Buy Points appeared first on Investor's Business Daily.